SteelPeak Wealth LLC Makes New $413,000 Investment in 10x Genomics, Inc. (NASDAQ:TXG)

SteelPeak Wealth LLC bought a new stake in 10x Genomics, Inc. (NASDAQ:TXG) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 21,247 shares of the company’s stock, valued at approximately $413,000.

Other hedge funds have also recently made changes to their positions in the company. Venrock Management VI LLC bought a new stake in shares of 10x Genomics in the fourth quarter valued at $117,894,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in 10x Genomics by 32.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,283,530 shares of the company’s stock worth $127,786,000 after buying an additional 565,059 shares in the last quarter. Bleakley Financial Group LLC purchased a new position in 10x Genomics during the fourth quarter worth about $234,000. Vanguard Group Inc. grew its position in 10x Genomics by 1.0% during the first quarter. Vanguard Group Inc. now owns 9,101,536 shares of the company’s stock worth $341,581,000 after buying an additional 90,204 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in 10x Genomics by 264.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 319,287 shares of the company’s stock worth $11,983,000 after buying an additional 231,697 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Stock Up 0.4 %

Shares of NASDAQ:TXG traded up $0.08 during trading on Friday, hitting $22.72. The stock had a trading volume of 75,555 shares, compared to its average volume of 1,665,193. 10x Genomics, Inc. has a 12 month low of $15.28 and a 12 month high of $57.90. The company has a market capitalization of $2.71 billion, a PE ratio of -10.15 and a beta of 1.84. The firm’s fifty day moving average is $19.41 and its 200 day moving average is $29.62.

Insider Transactions at 10x Genomics

In other news, CEO Serge Saxonov sold 4,877 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $118,511.10. Following the completion of the transaction, the chief executive officer now owns 889,641 shares of the company’s stock, valued at approximately $21,618,276.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Serge Saxonov sold 4,877 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total transaction of $118,511.10. Following the completion of the transaction, the chief executive officer now owns 889,641 shares of the company’s stock, valued at approximately $21,618,276.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,087 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total value of $99,314.10. Following the transaction, the insider now directly owns 350,055 shares of the company’s stock, valued at approximately $8,506,336.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,900 shares of company stock valued at $289,170. Corporate insiders own 10.03% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on TXG. UBS Group cut their price objective on 10x Genomics from $30.00 to $25.00 and set a “neutral” rating for the company in a report on Tuesday. Jefferies Financial Group upgraded 10x Genomics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a report on Monday, July 22nd. The Goldman Sachs Group dropped their target price on 10x Genomics from $26.00 to $16.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. Guggenheim restated a “neutral” rating on shares of 10x Genomics in a report on Tuesday, June 25th. Finally, Stifel Nicolaus dropped their target price on 10x Genomics from $53.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $31.46.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.